Paul J H L Peeters1, Marloes T Bazelier1, Hubert G M Leufkens1, Frank de Vries2, Marie L De Bruin3. 1. Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands. 2. Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, U.K. Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, the Netherlands. 3. Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands m.l.debruin@uu.nl.
Abstract
OBJECTIVE: To assess the risk of colorectal cancer associated with type 2 diabetes, as compared with a nondiabetic reference population, and to study additional associations between treatment stage and duration of obesity and colorectal cancer risk. RESEARCH DESIGN AND METHODS: We conducted an observational population-based cohort study within the Clinical Practice Research Datalink (1987-2012). All patients (≥18 years) with at least one prescription for an antidiabetic drug (n = 300,039) were matched (1:1) by birth year, sex, and practice to a comparison cohort without diabetes. Cox proportional hazards models were used to derive adjusted hazard ratios (HRs) for colorectal cancer associated with type 2 diabetes. Within the diabetic cohort, associations of colorectal cancer with treatment stages and duration of obesity (BMI ≥30 kg/m(2)) were studied. RESULTS: After a median follow-up of 4.5 years, 2,759 cases of colorectal cancer were observed among the diabetic study population. Type 2 diabetes was associated with a 1.3-fold increased risk of colorectal cancer (HR 1.26 [95% CI 1.18-1.33]). Among diabetic patients, no association was found with treatment stages. A trend of increased colorectal cancer risk was observed with longer duration of obesity. Risk of colorectal cancer was significantly increased for patients with recorded duration of obesity of 4-8 years (HR 1.19 [1.06-1.34]) and >8 years (1.28 [1.11-1.49]). CONCLUSIONS: Type 2 diabetes is associated with a moderately increased risk of colorectal cancer. Among diabetic patients, an increased risk was observed for patients who suffered from obesity for a total duration of 4 years or more.
OBJECTIVE: To assess the risk of colorectal cancer associated with type 2 diabetes, as compared with a nondiabetic reference population, and to study additional associations between treatment stage and duration of obesity and colorectal cancer risk. RESEARCH DESIGN AND METHODS: We conducted an observational population-based cohort study within the Clinical Practice Research Datalink (1987-2012). All patients (≥18 years) with at least one prescription for an antidiabetic drug (n = 300,039) were matched (1:1) by birth year, sex, and practice to a comparison cohort without diabetes. Cox proportional hazards models were used to derive adjusted hazard ratios (HRs) for colorectal cancer associated with type 2 diabetes. Within the diabetic cohort, associations of colorectal cancer with treatment stages and duration of obesity (BMI ≥30 kg/m(2)) were studied. RESULTS: After a median follow-up of 4.5 years, 2,759 cases of colorectal cancer were observed among the diabetic study population. Type 2 diabetes was associated with a 1.3-fold increased risk of colorectal cancer (HR 1.26 [95% CI 1.18-1.33]). Among diabeticpatients, no association was found with treatment stages. A trend of increased colorectal cancer risk was observed with longer duration of obesity. Risk of colorectal cancer was significantly increased for patients with recorded duration of obesity of 4-8 years (HR 1.19 [1.06-1.34]) and >8 years (1.28 [1.11-1.49]). CONCLUSIONS:Type 2 diabetes is associated with a moderately increased risk of colorectal cancer. Among diabeticpatients, an increased risk was observed for patients who suffered from obesity for a total duration of 4 years or more.
Authors: Phyo T Htoo; John B Buse; Mugdha Gokhale; M Alison Marquis; Virginia Pate; Til Stürmer Journal: Eur J Clin Pharmacol Date: 2016-05-10 Impact factor: 2.953
Authors: Eric E Low; Joshua Demb; Lin Liu; Ashley Earles; Ranier Bustamante; Christina D Williams; Dawn Provenzale; Tonya Kaltenbach; Andrew J Gawron; Maria Elena Martinez; Samir Gupta Journal: Gastroenterology Date: 2020-01-09 Impact factor: 22.682
Authors: Henning Hvid; Jonas Kildegaard; Kim Kristensen; Trine Porsgaard; Mikkel S Jørgensen; Borja Ballarín-González; Jonas Ahnfelt-Rønne; Bo F Hansen; Erica Nishimura Journal: J Diabetes Sci Technol Date: 2019-06-12